Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Phase 1

Terminated

Brief Summary: The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.

Detailed Description: The researchers hypothesize that the cyclinD1-interactome can be used to orient the use of fulvestrant in premenopausal and postmenopausal women. To test this hypothesis, the researchers propose a pre-surgical randomized clinical trial of tamoxifen vs fulvestrant in the window between breast cancer diagnosis on core biopsy and definitive surgery. Women with ER/cyclinD1 positive tumors will be eligible. Response to tamoxifen or fulvestrant will be evaluated using standard proliferation index as well as gene expression signatures obtained in pre-clinical models of tamoxifen resistance and sensitivity to fulvestrant. In addition, the researchers propose to use cutting edge new technology allowing ex-vivo expansion of primary culture from only a few cancer cells obtained by fine needle biopsy. The researchers propose to compare the response of these primary cells to patient response. If successful, the impact of this work can support the expansion of use of fulvestrant to not only postmenopausal women but premenopausal women as well. In addition, it may serve as a proof of principle to maximize the use of biopsy material to predict treatment response

Recruitment & Eligibility

Inclusion Criteria

Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements
Adult women greater than 18 years old
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer
- Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater
- Hormone receptor positive as defined as ≥ 10% positive stained cells
- HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status])
Tumor size at least 5 mm with planned primary surgery at Mount Sinai
A negative urine dipstick pregnancy test

Exclusion Criteria

Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells
Prior antiestrogen therapy
Tumor size less than 5 mm
Prior diagnosis of thrombosis or known hypercoagulable state
Known history of bleeding diathesis
Known liver disease
Prior treatment with neoadjuvant therapy
Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).
Current severe or uncontrolled systemic disease
Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.
Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.

Arm && Interventions

Group	Intervention	Description
Tamoxifen	Tamoxifen	20mg orally
Fulvestrant	Fulvestrant	750 mg injection in 3 divided doses

Primary Outcome Measures

Name	Time	Method
Change in Ki67 Cell Percentage	baseline and 2 weeks	The change in proliferation index as measured by the percentage of cells staining for Ki67 at 2 weeks as compared on baseline.

Secondary Outcome Measures

Name	Time	Method
Change in Estrogen Receptor Level	baseline and 2 weeks	The change in estrogen receptor level at 2 weeks as compared to baseline.
Incidence of Tamoxifen-resistance Gene Expression	2 weeks	Number of tamoxifen-resistance gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.
Percentage of Cells Staining Positive Within the Breast Tumor	2 weeks	Differential treatment effect for pre and post menopausal subjects assessed by the mean change in levels (expressed as a percentage of cells staining positive within the breast tumor) of ER (and PR) between pre-treatment and post-treatment stratified by menopausal status.
Change in Progesterone Receptor Level	baseline and 2 weeks	The change in progesterone receptor level at 2 weeks as compared to baseline.
Drug Dose Level	2 weeks	For samples that are available for culture in vivo, proliferation assay to test whether the cells derived from individual patients respond the same as the tumor in vivo in the same patient.
Incidence of Fulvestrant-sensitivity Gene Expression	2 weeks	Number of fulvestrant-sensitivity gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.

Locations (3): Mount Sinai West
🇺🇸
New York, New York, United States
Mount Sinai St. Luke's
🇺🇸
New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸
New York, New York, United States